Sanofi S.A.
Develops and markets pharmaceutical therapies across immunology, rare diseases, oncology, and vaccines including paediatric, respiratory, and combination formulations.
As of Aug 31, 2026
Summary
Sanofi is a major French pharmaceutical company with a market capitalisation of €92.6 billion, focused on prescription medicines, vaccines, and consumer healthcare. The stock is trading at €77.25 with a bullish technical bias, though it has lost 3.5% over the past year despite gaining 6.2% in the last month. Current momentum favours the upside on a technical reading.
Price history
As of Aug 28, 2026
Performance
+0.00%
-2.14%
+6.16%
+5.22%
-1.39%
-3.48%
As of Aug 28, 2026
Technical indicators
- 51.9
- 0.08Bullish
- 50: 76.05 · 200: 76.36
- €75.03 / €77.49
Technical Bias
Bullish lean
Sanofi's technical indicators present a mixed but slightly constructive picture: MACD is trending upward, whilst RSI sits near the midpoint and the 50 and 200-day moving averages offer limited directional clarity. This derived technical read suggests a tentatively bullish lean, though momentum remains unconfirmed and the stock trades just below the €77.49 resistance level.
A transparent read of the indicators below — not a prediction or recommendation.
As of Aug 28, 2026
Fundamentals
- €92.6B
- 23.84
- €3.24
- 8.09%
- +14.6%
- €8.99B
- 0.28
- €70.89 – €86.32
- 5.33%
- May 5, 2026
- Oct 30, 2026 (59 days)
As of Aug 31, 2026
Upcoming catalysts
- Earnings report
As of Aug 31, 2026
Latest news
As of Aug 31, 2026
MonkeyTrade's Take on Sanofi S.A.
Short-term outlook
Sanofi's short-term setup leans mildly constructive: MACD has flipped bullish and the stock is up 6.2% over the past month, though RSI at 51.9 and the flattening 50/200-day averages (76.05 vs 76.36) keep the picture from being decisive. A push through €77.49 resistance would strengthen the bullish case, while a slip back below €75.03 support would undercut it. No earnings catalyst is imminent, with the next report not due until October 2026.
Medium-term outlook
Sanofi's medium-term case leans constructive: 14.6% revenue growth alongside a bullish technical lean points to underlying momentum that the market hasn't fully priced in, even with a 23.84 P/E. The 5.3% dividend yield adds a steady income cushion while that growth plays out. A slip in the 8.1% profit margin would be the key signal to reassess this view.
Key risks
- A profit margin of +8.1% looks thin next to 14.6% revenue growth, suggesting cost pressures or investment spend are eating into profitability.
- The stock trades well below its 52-week high of €86.32, currently at €77.25, indicating the market has pulled back its valuation from recent peaks.
- A beta of 0.28 means Sanofi tends to move independently of broader market swings, which can limit upside participation even as it offers some ballast in downturns.
- The recent news flow around AimwellBio's AI portfolio and Sanofi's pilot involvement introduces exposure to early-stage ventures whose commercial payoff is unproven.
About Sanofi S.A.
Sanofi S.A. is a French pharmaceutical group listed on Euronext Paris under the ticker SAN, operating in the healthcare sector within the drug manufacturers industry. With a market capitalisation of €92.6 billion, it stands as one of the larger players in the global pharmaceutical space, reflecting its scale in developing and supplying medicines and vaccines across international markets.
Sanofi's key figures give a sense of how the market currently views the business. A price-to-earnings ratio of 23.84 shows what investors are paying relative to the company's earnings, while the dividend yield of +5.3% points to a notable level of income being returned to shareholders. Together, these figures offer a snapshot of Sanofi's valuation and shareholder returns as part of the broader healthcare sector.
How to trade Sanofi S.A.
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.